OBJECTIVES: Increasing numbers of youth are becoming HIV-infected and need highly active antiretroviral therapy (HAART). We hypothesized that behaviorally HIV-infected youth (BIY) ages 18 to 24 years are less likely than adults (25 years or older) to receive HAART and, once initiated, more likely to discontinue their first HAART regimen. METHODS: Longitudinal analysis of treatment-naïve patients (age 18 years or older) meeting criteria for HAART and followed at HIV Research Network sites (2002-2008). Time from meeting criteria to HAART initiation and duration on first regimen were assessed using Cox proportional hazards regression. RESULTS: A total of 3127 (268 youth, 2859 adult) treatment-naïve, HIV-infected patients met criteria. BIY were more likely to be black (66.8% vs 51.1%; P < 0.01) and less likely to identify injection drug use HIV risk (1.1% vs 8.8%; P < 0.01) than adults 25 years of age or older. Nearly 69% of BIY started HAART versus 79% of adults (P < 0.001). Adults 25 to 29 years of age (adjusted hazards ratio [AHR], 1.39; 95% confidence interval [CI], 1.12-1.73) and 50 years of age or older (AHR, 1.24; 95% CI, 1.00-1.54), but not 30 to 49 years (AHR, 1.19; 95% CI, 0.99-1.44) were more likely to initiate HAART than BIY. Attending four or more HIV provider visits within 1 year of meeting criteria was associated with HAART initiation (AHR, 1.91; 1.70-2.14). CD4 200 to 350 versus less than 200 cells/mm (AHR, 0.57; 95% CI, 0.52-0.63), and injection drug use (AHR, 0.80; 95% CI, 0.69-0.92) were associated with a lower likelihood of HAART initiation. There were no age-related differences in duration of the first regimen. CONCLUSION: BIY are less likely to start HAART when meeting treatment criteria. Addressing factors associated with this disparity is critical to improving care for youth.
OBJECTIVES: Increasing numbers of youth are becoming HIV-infected and need highly active antiretroviral therapy (HAART). We hypothesized that behaviorally HIV-infected youth (BIY) ages 18 to 24 years are less likely than adults (25 years or older) to receive HAART and, once initiated, more likely to discontinue their first HAART regimen. METHODS: Longitudinal analysis of treatment-naïve patients (age 18 years or older) meeting criteria for HAART and followed at HIV Research Network sites (2002-2008). Time from meeting criteria to HAART initiation and duration on first regimen were assessed using Cox proportional hazards regression. RESULTS: A total of 3127 (268 youth, 2859 adult) treatment-naïve, HIV-infectedpatients met criteria. BIY were more likely to be black (66.8% vs 51.1%; P < 0.01) and less likely to identify injection drug use HIV risk (1.1% vs 8.8%; P < 0.01) than adults 25 years of age or older. Nearly 69% of BIY started HAART versus 79% of adults (P < 0.001). Adults 25 to 29 years of age (adjusted hazards ratio [AHR], 1.39; 95% confidence interval [CI], 1.12-1.73) and 50 years of age or older (AHR, 1.24; 95% CI, 1.00-1.54), but not 30 to 49 years (AHR, 1.19; 95% CI, 0.99-1.44) were more likely to initiate HAART than BIY. Attending four or more HIV provider visits within 1 year of meeting criteria was associated with HAART initiation (AHR, 1.91; 1.70-2.14). CD4 200 to 350 versus less than 200 cells/mm (AHR, 0.57; 95% CI, 0.52-0.63), and injection drug use (AHR, 0.80; 95% CI, 0.69-0.92) were associated with a lower likelihood of HAART initiation. There were no age-related differences in duration of the first regimen. CONCLUSION:BIY are less likely to start HAART when meeting treatment criteria. Addressing factors associated with this disparity is critical to improving care for youth.
Authors: Robert L Johnson; Jaime Martinez; Geri Botwinick; Douglas Bell; Randall L Sell; Lawrence B Friedman; Sally Dodds; Kimberly Shaw; Carl Siciliano; Lynn E Walker; Jo L Sotheran Journal: J Adolesc Health Date: 2003-08 Impact factor: 5.012
Authors: Debra A Murphy; Moussa Sarr; Stephen J Durako; Anna-Barbara Moscicki; Craig M Wilson; Larry R Muenz Journal: Arch Pediatr Adolesc Med Date: 2003-03
Authors: Amanda Mocroft; Lidia Ruiz; Peter Reiss; Bruno Ledergerber; Christine Katlama; Adriano Lazzarin; Frank-Detlef Goebel; Andrew N Phillips; Bonaventura Clotet; Jens D Lundgren Journal: AIDS Date: 2003-08-15 Impact factor: 4.177
Authors: Marsha Lillie-Blanton; Valerie E Stone; Alison Snow Jones; Jeffrey Levi; Elizabeth T Golub; Mardge H Cohen; Nancy A Hessol; Tracey E Wilson Journal: Am J Public Health Date: 2009-11-12 Impact factor: 9.308
Authors: Charles Farmer; Baligh R Yehia; John A Fleishman; Richard Rutstein; W Christopher Mathews; Ank Nijhawan; Richard D Moore; Kelly A Gebo; Allison L Agwu Journal: J Pediatric Infect Dis Soc Date: 2014-10-19 Impact factor: 3.164
Authors: Ann-Margaret Dunn Navarra; Marya Viorst Gwadz; Robin Whittemore; Suzanne R Bakken; Charles M Cleland; Winslow Burleson; Susan Kaplan Jacobs; Gail D'Eramo Melkus Journal: AIDS Behav Date: 2017-11
Authors: Lana Lee; Baligh R Yehia; Aditya H Gaur; Richard Rutstein; Kelly Gebo; Jeanne C Keruly; Richard D Moore; Ank E Nijhawan; Allison L Agwu Journal: AIDS Patient Care STDS Date: 2016-03-16 Impact factor: 5.078
Authors: Melanie A Thompson; Michael J Mugavero; K Rivet Amico; Victoria A Cargill; Larry W Chang; Robert Gross; Catherine Orrell; Frederick L Altice; David R Bangsberg; John G Bartlett; Curt G Beckwith; Nadia Dowshen; Christopher M Gordon; Tim Horn; Princy Kumar; James D Scott; Michael J Stirratt; Robert H Remien; Jane M Simoni; Jean B Nachega Journal: Ann Intern Med Date: 2012-03-05 Impact factor: 25.391
Authors: Sophia A Hussen; Karen Andes; Danielle Gilliard; Rana Chakraborty; Carlos Del Rio; David J Malebranche Journal: Am J Public Health Date: 2014-06-12 Impact factor: 9.308